Advocacy intelligence hub — real-time data for patient organizations
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico — NA
Assistance Publique - Hôpitaux de Paris
University Hospital, Rouen
Takeda — PHASE2
Turkish Hematology Association
The First Affiliated Hospital of Soochow University
Takeda — PHASE3
CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Travel grants
Patient Assistance Programs1
Cablivi
Genzyme Corporation
Travel Grants1
Accessia Health: Thrombotic Thrombocytopenic Purpura (TTP) - Public Insurance
Accessia Health
Cablivi
(CAPLACIZUMAB)Orphan drugGenzyme Corporation
12.1 Mechanism of Action Caplacizumab-yhdp targets the A1-domain of vWF, and inhibits the interaction between vWF and platelets, thereby reducing both...
Ilaria Mancini, PhD
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lucas Kühne, MD
Department II of Internal Medicine, University Hospital of Cologne
Abdulgabar Salama, MD
Universitätsklinikum Charite, Med. Fakultät der Humboldt-Universität Berlin
Ming Hou, PhD
Qilu Hospital of Shandong University
Wolfgang Frenzel, MD
International Medical Director
lei zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital